Charles Geyer

基本信息

Career Trajectory

Bio

board-certified medical oncologist with expertise in the design and conduct of phase III clinical trials and the study and treatment of breast cancer.

He is a Fellow of the American College of Physicians and member of the American Society of Clinical Oncology and the American Association for Cancer Research.

Research Interests

Papers共 310 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

Switching to T-DM1 Remains Justified in Patients with HER2-negative Residual Invasive Breast Cancer after Neoadjuvant Therapy

Charles E Geyer,Sibylle Loibl

Breast (Edinburgh, Scotland) (2025): 104450-104450

Cited0Views0WOSBibtex

Abstract PO2-11-06: Anti-Müllerian Hormone in Young Women with Breast CAncer to Predict Permanent Loss of Ovarian Function after Chemotherapy and Anti-Her2 Therapy (AMYCA): a Biomarker Analysis of the BETH and KAITLIN Trials

Matteo Lambertini, Deirdre Allegranza, Ruediger Laubender,Nadia Harbeck,Sandra Swain,Charles Geyer,Dennis Slamon, Gabriella Bobba,Chiara Lambertini,Sanne Lysbet De Haas,Eleonora Restuccia,Ines Vaz Luis,David Cameron,Ian Krop,Eric Winer,Richard Anderson

Cancer Research（2024）

Cited0Views0Bibtex

Long-term Outcomes by Lobular Versus Ductal Histology in Four NSABP Adjuvant Breast Cancer Trials

Julia Foldi,Neil Carleton,Stewart J Anderson,Priya Rastogi,Adrian Lee,Marija Balic,Charles E Geyer,Steffi Oesterreich,Norman Wolmark

Journal of the National Cancer Institute（2024）

Cited0Views0WOSBibtex

Abstract GS03-12: Phase III Study of Adjuvant Ado-Trastuzumab Emtansine Vs Trastuzumab for Residual Invasive HER2-positive Early Breast Cancer after Neoadjuvant Chemotherapy and HER2-targeted Therapy: KATHERINE Final IDFS and Updated OS Analysis

Sibylle Loibl,Max Mano,Michael Untch,Chiun-Shen Huang,Eleftherios Mamounas,Norman Wolmark,Adam Knott,Asna Siddiqui,Thomas Boulet,Beatrice Nyawira,Eleonora Restuccia,Charles Geyer

Cancer Researchno. 9_Supplement (2024): GS03-12

Cited2Views0Bibtex

Clinical and Genomic Risk for Late Breast Cancer Recurrence and Survival

NEJM evidenceno. 8 (2024): EVIDoa2300267-EVIDoa2300267

Cited1Views0WOSBibtex

Phase III Study of Adjuvant Ado-Trastuzumab Emtansine Vs Trastuzumab for Residual Invasive HER2-positive Early Breast Cancer after Neoadjuvant Chemotherapy and HER2-targeted Therapy: KATHERINE Final IDFS and Updated OS Analysis

Michael Untch,Sibylle Loibl,Max S. Mano,Chiun-Sheng Huang,Eleftherios P. Mamounas,Norman Wolmark,Adam Knott,Asna Siddiqui,Thomas Boulet,Beatrice Nyawira,Eleonora Restuccia,Charles E. Geyer

ONCOLOGY RESEARCH AND TREATMENT（2024）

Cited0Views0Bibtex

Anti-Mullerian Hormone in Young Women with Breast CAncer to Predict Permanent Loss of Ovarian Function after Chemotherapy and Anti-Her2 Therapy (AMYCA): a Biomarker Analysis of the BETH and KAITLIN Trials

CANCER RESEARCHno. 9 (2024)

Cited0Views0Bibtex

Abstract PO1-02-02: Update of RSClin with Extended TAILORx Follow-Up and Development and Validation of a New Tool for Risk of Late Distant Recurrence

Joseph Sparano,Michael Crager,Robert Gray,Gong Tang,Jess Hoag,Frederick Baehner,Charles Geyer,Steven Shak,Norman Wolmark,Salomon Stemmer

Cancer Researchno. 9_Supplement (2024): PO1-02

Cited0Views0Bibtex

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn

Professor

Papers共 310 篇Author StatisticsCo-AuthorSimilar Experts